Phenotyping of tumor biology in patients by multimodality multiparametric imaging: Relationship of microcirculation, αvβ3 expression, and glucose metabolism

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1691-1698

  Metz, Stephan ^a   Ganter, Carl ^a   Lorenzen, Sylvie ^a   Van Marwick, Sandra ^b   Herrmann, Ken ^b   Lordick, Florian ^a   Nekolla, Stephan G ^b   Rummeny, Ernst J ^a   Wester, Hans Jürgen ^b   Brix, Gunnar ^c   Schwaiger, Markus ^b   Beer, Ambros J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

Author keywords

18F FDG; 18F galacto RGD; Angiogenesis; DCE MRI; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GALACTO RGD F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADRENAL METASTASIS; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BLOOD VOLUME; BONE METASTASIS; BRONCHUS CARCINOID; CANCER CELL POPULATION HETEROGENEITY; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC HETEROGENEITY; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; IMAGING; KIDNEY CARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MICROCIRCULATION; MULTIMODALITY MULTIPARAMETRIC IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PELVIS CANCER; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; DIAGNOSTIC IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; INTEGRIN ALPHAVBETA3; MAGNETIC RESONANCE IMAGING; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASMS; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; TUMOR BURDEN;

EID: 79851480446     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.077719     Document Type: Article

References (33)

1. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189-195. (Pubitemid 46160619)
2. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol. 2006;24:3282-3292. (Pubitemid 46622068)
3. Rose CJ, Mills SJ, O'Connor JP, et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med. 2009;62:488-499.
4. Jeswani T, Padhani AR. Imaging tumour angiogenesis. Cancer Imaging. 2005;5:131-138.
5. O'Donnell A, Padhani A, Hayes C, et al. A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005;93:876-883. (Pubitemid 41487012)
6. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24:769-777. (Pubitemid 46622044)
7. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer. 2005;92:1599-1610. (Pubitemid 40756468)
8. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev. 2008;27:631-644.
9. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
10. 18F] galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
11. Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer. 2006;4:299-302. (Pubitemid 43779890)
12. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
13. Bokacheva L, Huang AJ, Chen Q, et al. Single breath-hold T1 measurement using low flip angle TrueFISP. Magn Reson Med. 2006;55:1186-1190.
14. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
15. 18F]galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
16. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32:663-671. (Pubitemid 41502970)
17. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol. 2000;27:683-687.
18. Souvatzoglou M, Ziegler SI, Martinez MJ, et al. Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. Eur J Nucl Med Mol Imaging. 2007;34:405-412. (Pubitemid 46295346)
19. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771-1777. (Pubitemid 29523568)
20. 18F-FDG. J Nucl Med. 2008;49:22-29.
21. Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med. 2004;52:420-429. (Pubitemid 39025290)
22. Brix G, Zwick S, Kiessling F, Griebel J. Pharmacokinetic analysis of tissue microcirculation using nested models: multimodel inference and parameter identifiability. Med Phys. 2009;36:2923-2933.
23. Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 2 - correlation between subjects. BMJ. 1995;310:633.
24. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
25. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
26. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
27. Miles KA, Griffiths MR, Keith CJ. Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:22-28. (Pubitemid 41785305)
28. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8:918-921.
29. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5:127-135.
30. Nakamura I, Pilkington MF, Lakkakorpi PT, et al. Role of alpha(v)beta(3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci. 1999;112:3985-3993.
31. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616. (Pubitemid 350206795)
32. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging. 2006;33(suppl 1):44-53.
33. Judenhofer MS, Wehrl HF, Newport DF, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008;14:459-465. (Pubitemid 351499385)